Results 241 to 250 of about 35,970 (259)

Variation in Early Anakinra Use and Short‐Term Outcomes in Multisystem Inflammatory Syndrome in Children

Arthritis & Rheumatology, 2023
Evidence regarding effectiveness of interleukin‐1 receptor antagonism in multisystem inflammatory syndrome in children (MIS‐C) is lacking. We characterized variation in initial treatment with anakinra and evaluated cardiovascular outcomes associated with
Joyce C. Chang, C. C. Young, E. Muscal, S. S. Sexson Tejtel, M. Newhams, Suden Kucukak, H. Crandall, A. Maddux, C. Rowan, N. Halasa, H. Harvey, C. Hobbs, M. Hall, M. Kong, Cassyanne L. Aguiar, J. Schuster, J. Fitzgerald, Aalok R. Singh, Kari Wellnitz, Ryan A. Nofziger, N. Cvijanovich, E. Mack, A. Schwarz, S. Heidemann, J. Newburger, Laura D. Zambrano, A. Campbell, M. Patel, A. Randolph, M. Son   +29 more
semanticscholar   +1 more source

Anakinra was not associated with lower mortality in hospitalised COVID‐19 patients: A systematic review and meta‐analysis of randomized controlled trials

Reviews in Medical Virology, 2023
The Coronavirus disease‐2019 (COVID‐19) pandemic continues, and the death toll continues to surge. This meta‐analysis aimed to determine the efficacy of anakinra on mortality in patients with COVID‐19.
W. Shang, Yingying Zhang, Guizuo Wang, Dong Han   +3 more
semanticscholar   +1 more source

Anakinra-An Interleukin-1 Receptor Antagonist for COVID-19.

American Journal of Therapeutics, 2023
BACKGROUND Coronavirus disease (COVID-19) caused by SARS-CoV-2 virus caused a global pandemic in 2019. There are limited pharmacologic options available.
Timothy Nguyen, L. Dima, Kristine C. Willett   +2 more
semanticscholar   +1 more source

Early anakinra treatment improves cardiac outcome of multisystem inflammatory syndrome in children regardless of disease severity.

Rheumatology, 2023
OBJECTIVES The main aim of this study was to define the best treatment option for multisystem inflammatory syndrome in children (MIS-C) and to analyze the role of anakinra. METHODS This is a multicentre retrospective cohort study. Patients were treated
A. Taddio, S. Della Paolera, L. Abbagnato, A. Agrusti, R. Badolato, Francesca Biscaro, R. Caorsi, A. Consolaro, R. D. Delle Piane, M. Fabi, Ilenia Floretta, M. Gattorno, M. Giangreco, F. La Torre, M. Maggio, Lorenzo Mambelli, A. Mauro, M. V. Mastrolia, A. Meneghel, D. Montin, F. Ricci, G. Simonini, A. Smarrazzo, R. Sottile, S. Stucchi, M. Tardi, L. Verdoni, G. Zuccotti, Fiammetta Zunica, A. Ravelli, M. Cattalini   +30 more
semanticscholar   +1 more source

Anakinra‐Associated Systemic Amyloidosis

Arthritis & Rheumatology, 2023
To describe a 41‐year‐old woman with a history of neonatal onset multisystem inflammatory disease, on treatment with daily subcutaneous injections of 600 mg of recombinant interleukin‐1 receptor antagonist (IL‐1Ra) protein, anakinra, since the age of 28,
S. Alehashemi, Surendra Dasari, Anvitha R Metpally, Katsiaryna Uss, L. Castelo-Soccio, T. Heller, P. Kellman, Marcus Y. Chen, M. Ahlman, Jeff Kim, S. Wargo, D. Kuhns, D. Fink, A. D. de Jesus, Paul S. Martin, R. Chang, Jonathan Bolaños, C. Lee, S. Nasr, R. Goldbach-Mansky, E. McPhail   +20 more
semanticscholar   +1 more source

Benefit of Anakinra in Treating Pediatric Secondary Hemophagocytic Lymphohistiocytosis

Arthritis & Rheumatology, 2020
To assess the benefit of the recombinant human interleukin‐1 receptor antagonist anakinra in treating pediatric patients with secondary hemophagocytic lymphohistiocytosis (HLH)/macrophage activation syndrome (MAS) associated with rheumatic and ...
E. Eloseily, P. Weiser, C. Crayne, H. Haines, M. Mannion, M. Stoll, T. Beukelman, T. Atkinson, R. Cron   +8 more
semanticscholar   +1 more source

Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review

European Journal of Haematology, 2023
Haemophagocytic lymphohistiocytosis (HLH) or macrophage activation syndrome (MAS) has a potentially high mortality rate. Anakinra, an interleukin‐1 receptor antagonist, is now recommended early in HLH/MAS, with intravenous (IV) use proposed in critically
J. Charlesworth, A. Kavirayani
semanticscholar   +1 more source